TerminatedNo phase
Role of Glycation and Inflammation in Acute Ischemic Heart Disease
Key facts
- Who runs it
- GEK Srl
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 16 people enrolled
- Started
- 1 Feb 2022
- Ended
- 31 Dec 2023
- Type of study
- Observational
- Treatments tested
- BAFF and MGO
- Record updated
- 16 February 2024
- Why it stopped
- Missing enrollment at study centre
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- hospitalization for first myocardial infarction (STEMI or NSTEMI)
- age between 18 and 80
Who cannot take part
- chronic anti-inflammatory treatment for autoimmune disease (i.e. DMARDs, high dose FANS, cortisonic drugs)
- uncompensated T2DM (HbA1c >53mmol/mol)
- use of anti-CD20 treatment
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study requires the consecutive enrollment of 60 patients following the first event of acute myocardial infarction, evaluating B-Cell Activating Factor (BAFF) and methylglyoxal (MGO) levels in the acute setting (pre-reperfusion) and 3 months after reperfusion.
The group in the trial
- First Ischemic Cardiac Event
Measurement of BAFF and MGO at hospitalization (before reperfusion) and after 3 months during follow-up
Treatment: BAFF and MGO
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Action of Glycation and Inflammation in Operative Ischemic Heart Disease
- Record updated
- 16 February 2024